/
Neurology
Delirium
45
Pipeline Programs↗
82
Active Trials↗
19
Companies Involved↗
Delirium is a moderately active landscape with 45 programs across 19 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Bristol-Myers Squibb, Wanbangde Pharmaceutical Group Co., LTD. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical32
Phase 23
Phase 39
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
40 of 41 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 93% of 45 pipeline programs.
Analysis
Trial Status
305
clinical trials
Completed130 · 43%
Unknown status54 · 18%
Recruiting42 · 14%
Not yet recruiting27 · 9%
Terminated24 · 8%
Withdrawn14 · 5%
Other14 · 5%
Clinical Trials
Trial Activity
305 trials
MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children. The MELA-PAED Trial: a Randomized, Double-blind, Placebo-controlled Trial.
Recruiting·—·Phase 3·NCT05541276·676 enrolled
The PREVENT AGITATION Trial II - Children ≤1 Year
Recruiting·—·Preclinical·NCT05091242·336 enrolled
Page 1 of 21
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)